OmniAb, Inc. (OABI)
- Previous Close
4.6400 - Open
4.6200 - Bid 4.5400 x 200
- Ask 4.5900 x 100
- Day's Range
4.5350 - 4.6250 - 52 Week Range
3.1400 - 6.7150 - Volume
450,236 - Avg. Volume
483,441 - Market Cap (intraday)
542.293M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.00
OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
www.omniab.comRecent News: OABI
Performance Overview: OABI
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OABI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OABI
Valuation Measures
Market Cap
534.09M
Enterprise Value
472.67M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
13.31
Price/Book (mrq)
1.70
Enterprise Value/Revenue
13.84
Enterprise Value/EBITDA
-9.47
Financial Highlights
Profitability and Income Statement
Profit Margin
-148.16%
Return on Assets (ttm)
-10.86%
Return on Equity (ttm)
-15.43%
Revenue (ttm)
34.16M
Net Income Avi to Common (ttm)
-50.62M
Diluted EPS (ttm)
-0.5000
Balance Sheet and Cash Flow
Total Cash (mrq)
86.98M
Total Debt/Equity (mrq)
8.12%
Levered Free Cash Flow (ttm)
23.56M
Research Analysis: OABI
Company Insights: OABI
OABI does not have Company Insights